Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in patients with Hodgkin Lymphoma.

Statements

Source and description
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous hematopoietic stem cell transplant (ASCT).
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkins Lymphoma (HL) following autologous stem cell transplant (ASCT).
Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkins Lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
Adcetris (brentuximab vedotin) [product information]. EMA. The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).
Adcetris (brentuximab vedotin) [product information]. EMA. The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.